Logo
Login
$ACRS
$3.79 +$0.04 (1.07%) Close

Ownership

13F as of Q2 2026 · 147.2M shares outstanding

Who owns ACRS?

By type of holder
Institutions 80.6% Insiders 19.4% Everyone else 0.0%
Concentration Top 10 holders own 76.3%
Leonard Braden Michael 28.7% · BML Capital Management, LLC 8.1%
Institutional ownership
80.6%
+6.8 pts vs last qtr
Institutional holders
146
+10 vs last qtr
Net shares bought
+9.9M
by institutions in Q2 2026
New / sold out
27 / 17
positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026
  • Ra Capital Management, L.P. +5.9M
  • BlackRock, Inc. +2.6M

Sign up to see all 5.

Biggest sellers in Q2 2026
  • Morgan Stanley −2.6M
  • BML Capital Management, LLC −2.3M

Sign up to see all 5.

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Aclaris Therapeutics, Inc. in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2019–FY2025
+196.6%
+19.87% a year
Each share's claim on the business
−66.3%
shrank without buying or selling a share
Spent on buybacks vs paid in stock
— vs $100M
over 7 fiscal years
Diluted shares, split-adjusted
40.1M81.9M123.8M2019: 41.3M shares'192020: 42.5M shares'202021: 56.7M shares'212022: 65.2M shares'222023: 69.8M shares'232024: 77.3M shares'242025: 122.6M shares'25
Buybacks Stock-based comp
$0$10.3M$20.5M2019 buybacks: $02019 stock comp: $16.2M'192020 buybacks: $02020 stock comp: $11.2M'202021 buybacks: $02021 stock comp: $14.1M'212022 buybacks: $02022 stock comp: $15.0M'222023 buybacks: $02023 stock comp: $20.5M'232024 buybacks: $02024 stock comp: $10.9M'242025 buybacks: $02025 stock comp: $12.4M'25

How patient are the owners?

Institutional shares by how long they've been held
5+ years32% 3–5 years1% 1–3 years30% Under 1 year38%
Quarterly turnover
15.4%
of institutional shares changed hands
Top 10 managers, median time held
1.5 years

Super Investors

Investment managers reporting ACRS on Form 13F
BC
BML Capital Management, LLC
Shares
12.0M
% of company
8.14%
Change vs last qtr
−2.3M (−16.0%)
Held since
2023
RC
Ra Capital Management, L.P.
Shares
12.7M
% of company
8.64%
Change vs last qtr
+5.9M (+87.0%)
Held since
Q1 '26

28 more super investors behind a free account

See every manager holding Aclaris Therapeutics, Inc., how their position has changed, and how long they've held it.

Sign up free

Institutional Funds

Mutual funds and ETFs reporting ACRS on Form N-PORT; together they hold 14.4% of the company
VT
Vanguard Total Stock Market Index Fund
Vanguard Index Funds
Position value
$22.4M
% of company
2.88%
% of the fund
0.00%
As of
June 30, 2026
IR
iShares Russell 2000 ETF
iShares Trust
Position value
$16.4M
% of company
2.10%
% of the fund
0.02%
As of
June 30, 2026

23 more funds behind a free account

See every fund holding Aclaris Therapeutics, Inc. and how much of the fund the position is.

Sign up free

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G
LB
Leonard Braden Michael
Insider
Shares
42.2M
% of company
28.70%
Change vs last qtr
—
Held since
—
MA
Mehra Anand
Insider
Shares
4.2M
% of company
2.84%
Change vs last qtr
—
Held since
—

12 more holders behind a free account

See every insider and 5%+ holder of Aclaris Therapeutics, Inc..

Sign up free

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans